Mark S Segal, MD, PhD - Research

Research at a glance

Top areas of exploration

Cells, Cultured , 19 publications
Biomarkers , 17 publications
Kidney Failure, Chronic , 16 publications
Hypertension , 16 publications

Research activity

161 publications

10,466 citations

Why is this important?

Active clinical trials

HyperQure RDN System

HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 22 Years - 80 Years
Sexes: All

EASi-KIDNEY

Investigator: Mark S Segal
Status: Accepting Candidates

REGEN-006

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 30 Years - 80 Years
Sexes: All

My publications

161 publications

2015

Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease.

PloS one

鈥�

2015

Mild renal dysfunction and long-term adverse outcomes in women with chest pain: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE).

American heart journal

鈥�

2015

Renal function and coronary microvascular dysfunction in women with symptoms/signs of ischemia.

PloS one

鈥�

2015

The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic.

Journal of the American Society of Hypertension : JASH

鈥�

2014

End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Arthritis & rheumatology (Hoboken, N.J.)

鈥�

网红黑料